Ozon Pharmaceuticals

Ozon Pharmaceuticals is a Russian manufacturer of pharmaceuticals. The product range is represented in all pharmaceutical niches: traditional low molecular weight pharmaceuticals, production of highly toxic drugs against oncology and complex science-intensive drugs in the field of biotechnology. It produces more than 350 items of finished pharmaceuticals, with an annual output of about 5 billion units.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ozon Pharmaceuticals balance sheet

Report period2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ozon Pharmaceuticals cash flows

Report period2021 2022 2023 Q2 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ozon Pharmaceuticals multipliers

Report period2021 2022 2023 Q2 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Ozon Pharmaceuticals profitability

Report period2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Ozon Pharmaceuticals assets
Ozon Pharmaceuticals cash flows
Ozon Pharmaceuticals dividends
0%

Ozon Pharmaceuticals dividend policy

The criterion for dividend payment is the Net Debt / EBITDA ratio. The dividend policy envisages the following scenarios: Net Debt / EBITDA > 3x - no dividends are paid; 2x < Net Debt / EBITDA ≤ 3x - at least 15% of Net Profit; 1x < Net Debt / EBITDA ≤ 2x - at least 25% of Net Profit; 0x < Net Profit / EBITDA ≤ 1x - at least 35% of Net Profit, but not more than 100% of free cash flow; Net Profit / EBITDA = 0x - at least 50% of Net Profit, but not more than 100% of free cash flow.

Ozon Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
OZPH:RMOzon PharmaceuticalsCommon shareRUB 0.02RU000A109B25RUB 28.19

Ozon Pharmaceuticals bonds

NameIssue sizePriceYield
Ozon 001P-01 (RUB)1,000,000 pcs.95.74%14.05%
Ozon 001P-02 (RUB)700,000 pcs.89%18.73%
Share capital structure of Ozon Pharmaceuticals
Ozon Pharmaceuticals news
31.10.2024
Ozone Pharmaceuticals' RAS net profit for 9 months of 2024 amounted to ₽1.51 billion, up 49.5% from ₽1.01 billion in the previous year. Revenue increased 58.7% to ₽1.65 billion compared to ₽1.04 billion a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
17.10.2024
Ozone Pharmaceuticals has set the IPO offering price at ₽35 per share, which corresponds to the top end of its price range and a capitalization of ₽38.5 billion. Total IPO size was ₽3.45 billion. Raised funds will be for the expansion of its generic and biosimilars product line and the launch of new manufacturing facilities. Trading of the shares will begin...
Source: {source} pictogram ozonpharm.ru
Pictogram next
11.10.2024
Ozone Pharmaceuticals has set the IPO price range at ₽30-35 per share, which corresponds to a capitalization of ₽30-35 billion. Investors are offered additional issue shares of up to 10% of the share capital. Collection of applications for participation in the IPO begins today and will last until October 16. Trading in the shares will begin on October 17 und...
Source: {source} pictogram ozonpharm.ru
Pictogram next
All Ozon Pharmaceuticals news
General information
Company nameOzon Pharmaceuticals
Tags#pharmacy, #biotechnology, #ipo2024
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressRF, Samarskaya oblast, g. Zhigulevsk, ul. Gidrostroiteley, d. 6
Mailing address445351, Samarskaya oblast, g. Zhigulevsk, ul. Gidrostroiteley, d. 6
Websiteozonpharm.ru
Information disclosuree-disclosure.ru